Details of the Drug
General Information of Drug (ID: DMXWUHA)
| Drug Name |
Ribostamycin
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
ribostamycin; Vistamycin; Hetangmycin; Xylostatin; Antibiotic SF 733; Ribostamycinum; Ribostamicina; Ribostamycine; Ribastamin; Dekamycin IV; SF 733; 25546-65-0; ribostamycin A; Ribostamycin [INN:BAN]; Bu 1709; Ribostamycine [INN-French]; Ribostamycinum [INN-Latin]; UNII-2Q5JOU7T53; SF-733; Ribostamicina [INN-Spanish]; C17H34N4O10; EINECS 247-091-5; NSC 138925; BRN 1357280; 2Q5JOU7T53; CHEBI:45257; NSC138925; O-2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)-O-(beta-D-ribofuranosyl-(1->5))-2-deoxystreptamine
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Affected Organisms |
Enteric bacteria and other eubacteriaHumans and other mammals
|
||||||||||||||||||
| ATC Code | |||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 454.5 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -6.3 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 10 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 14 | ||||||||||||||||||
| ADMET Property |
|
||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||


